DepoMed (DEPO) reported earnings on Mon 7 Aug 2017 (a/h)

Depomed, Inc. is an American specialty pharmaceutical company which mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California.

• depomed.com

** charts after earnings **

  

DepoMed misses by $0.04, reports revs in-line; lowers FY17 guidance

• Reports Q2 (Jun) adj. earnings of $0.08 per share, $0.04 worse than the Capital IQ Consensus of $0.12; revenues fell 14.3% year/year to $100 mln vs the $100.4 mln Capital IQ Consensus.
• Co issues downside guidance for FY17, sees FY17 revs of $395-410 mln vs. $417.83 mln Capital IQ Consensus Estimate; EBITDA to $107-117 mln from $120-130 mln.
• The Company is reinvesting in its neurology salesforce which is focused on Gralise and Cambia. The team is growing from 40 to 90 sales representatives effective September 1st. This investment, which will increase SG&A expense in the second half of the year, is designed to advance the Company's initiative to strengthen its neurology platform and create a more diversified business.